EMA Authorised: Lokelma (sodium zirconium cyclosilicate) — AstraZeneca AB

View source ↗

Summary

The EMA authorised Lokelma (sodium zirconium cyclosilicate) from AstraZeneca AB for the treatment of hyperkalemia in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperkalemia

Drugs mentioned

• Lokelma (sodium zirconium cyclosilicate)

Snippet

Status: Authorised. Therapeutic area: Hyperkalemia. MAH: AstraZeneca AB. Decision date: 24/07/2025